[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602062":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":46,"responsibleParty":63,"collaborators":44,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":44,"enrollmentInfo":76,"targetDuration":44,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":48,"whyStopped":44,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Brown University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Study drug","EXPERIMENTAL","Probenecid 2gr oral",[13],"Drug: Probenecid Oral Tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo inactive",[19],"Drug: Placebo Oral Tablet",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Probenecid Oral Tablet","2gr daily",[9],[27],"Probalan",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo Oral Tablet","Inactive compound",[15],[33],"Matching Inactive Oral Tablet",[35],{"name":36,"affiliation":37,"role":38},"Carolina Haass-Koffler, PharmD, PhD","Brown Univiversity","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Brian Gully, MA","CONTACT","401-863-6646",null,"brian_gully@brown.edu",[47],{"facility":5,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Providence","Rhode Island","02903","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-71.41283,41.82399,{"lat":58,"lon":57},[61],{"name":41,"role":42,"phone":44,"phoneExt":44,"email":62},"alcohol-stress-study@brown.edu",{"type":38,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"Carolina L Haass-Koffler","Associate Professor","100602062","phase-2-probenecid-administration-for-alcohol-craving-and-consumption-100602062",false,"NCT07118618","Probenecid Administration for Alcohol Craving and Consumption","Probenecid, Pannexin 1 Channels for Alcohol Use Disorder","PROB2","Inclusion Criteria:\n\n* • Male or female, ≥18 years.\n\n  * women \\>7 drinks\u002Fweek; men \\>14 drinks\u002Fweek.\n  * meet moderate to severe AUD score for DSM-5 criteria.\n  * Breath Alcohol Content (BrAC)=0.00 at each visit.\n  * in good health as confirmed by medical history, physical examination and lab tests.\n  * willing to adhere to the study procedures.\n  * understand informed consent and questionnaires in English at an 8th grade level.\n\nExclusion Criteria:\n\n* • Women who are breastfeeding or positive urine test for pregnancy.\n\n  * clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin \\>150% of the upper normal limit, ALT\u002FAST \\>300% the UNL, creatinine clearance ≤60 dl\u002Fmin\n  * meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses\n  * medications that reduce alcohol consumption (naltrexone, disulfiram).\n  * use aspirin (salicylates may reduce effect of probenecid), penicillin, methotrexate (may increase concentration).\n  * history of suicide attempts in the last three years.\n  * current diagnosis of a moderate or severe cannabis use disorder as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline.\n  * current diagnosis of another substance disorder at any severity, other than nicotine, as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline.\n  * current use of medications that may interact with probenecid.\n  * history of hypersensitivity to sulfa drugs.","ALL","18 Years",{"count":77,"type":78},120,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g \u002Fday) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.",[84,85,86],"Alcohol Use Disorder (AUD)","Alcohol Consumption","Craving",[88,89,86,90],"AUD","Probenecid","Alcohol","2026-03-14",{"date":93,"type":94},"2026-03-17","ACTUAL",{"date":91,"type":94},{"date":97,"type":78},"2030-12-31",{"name":5,"class":6},1]